Literature DB >> 11014385

Myxedema coma of both primary and secondary origin, with non-classic presentation and extremely elevated creatine kinase.

S Benvenga1, S Squadrito, F Saporito, A Cimino, F Arrigo, F Trimarchi.   

Abstract

Myxedema coma is a rare, often fatal endocrine emergency that concerns elderly patients with long-standing primary hypothyroidism; myxedema coma of central origin is exceedingly rare. Here, we report a 37-year-old woman in whom classical symptoms of hypothyroidism had been absent. Six years earlier, she had severe obstetric hemorrhage and, shortly after, two subsequent episodes of pericardial effusion. On the day of admission, pericardiocentesis was performed for the third episode of pericardial effusion. Because of the subsequent grave arrhythmias and unconsciousness, she was transferred to our ICU. Prior to the endocrine consultation, a silent myocardial infarction had been suspected, based on the extremely high serum levels of creatine kinase (CK) and isoenzyme CK-MB. However, based on thyroid sonography, pituitary computed tomography, elevated titers of antithyroid antibodies and pituitary stimulation tests, the final diagnosis was myxedema coma of dual origin: an atrophic variant of Hashimoto's thyroiditis and post-necrotic pituitary atrophy (Sheehan syndrome). Substitutive therapy caused a prompt clinical amelioration and normalization of CK levels. Our patient is the first case of myxedema coma of double etiology, and illustrates how its presentation deviates markedly from the one endocrinologists and physicians at ICU are prepared to encounter. In addition, cardiac problems as those of our patient should not discourage from substitutive treatment (using L-thyroxine and the gastrointestinal route of absorption), if the age is relatively low.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014385     DOI: 10.1055/s-2007-978654

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Hypothermia with loss of consciousness and hyponatraemia.

Authors:  E Incasa; M Tampieri; A Zangirolami; S Gamberini; V Di Chiara; B Boari; S Tartari; G Benea; E Righini; R Manfredini; P A Modesti
Journal:  Intern Emerg Med       Date:  2007-06       Impact factor: 3.397

Review 2.  Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions.

Authors:  Ulla Feldt-Rasmussen; Marianne Klose; Salvatore Benvenga
Journal:  Endocrine       Date:  2018-09-06       Impact factor: 3.633

3.  Myxedema Coma Associated with Macroprolactinoma: Case Report and Review of the Literature.

Authors:  Elizabeth Jasola Omoniyi; Richard J Robbins
Journal:  Case Rep Endocrinol       Date:  2022-04-28

4.  Predictors of outcome in myxoedema coma.

Authors:  Jennifer Beynon; Simeen Akhtar; Tara Kearney
Journal:  Crit Care       Date:  2008-01-23       Impact factor: 9.097

5.  Sudden Cardiac Arrest in a Patient With Myxedema Coma and COVID-19.

Authors:  Neal M Dixit; Katie P Truong; Soniya V Rabadia; David Li; Pratyaksh K Srivastava; Tina Mosaferi; Marcella A Calfon Press; Ines Donangelo; Theodoros Kelesidis
Journal:  J Endocr Soc       Date:  2020-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.